<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755231</url>
  </required_header>
  <id_info>
    <org_study_id>ILH297-C004</org_study_id>
    <nct_id>NCT04755231</nct_id>
  </id_info>
  <brief_title>Post-Market Clinical Study of the PanOptix Intraocular Lens (IOL) in a Chinese Population</brief_title>
  <official_title>Post-Market Clinical Study of the AcrySof® IQ PanOptix® Presbyopia Correcting Intraocular Lens in a Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to assess the clinical performance of the&#xD;
      PanOptix IOL in a Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical study, subjects will be implanted with the PanOptix IOL in both eyes. The&#xD;
      second eye surgery will occur 7-28 days after the first eye. A total of 11 scheduled visits&#xD;
      are planned, including a screening visit, two operative visits, and 8 postoperative visits.&#xD;
      The total expected duration of the subject's participation will be about 14 months. This&#xD;
      study will be conducted in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of eyes with Best Corrected Distance Visual Acuity (BCDVA) of 0.3 LogMAR or better</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean monocular and binocular BCDVA</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean monocular and binocular Distance Corrected Intermediate Visual Acuity (DCIVA) (60 cm)</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean monocular and binocular Distance Corrected Near Visual Acuity (DCNVA) (40 cm)</measure>
    <time_frame>Month 6 post second eye implantation</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Aphakia</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>PanOptix IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcrySof IQ PanOptix Presbyopia Correcting IOL implanted in the capsular bag in the posterior chamber of the eye during cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcrySof IQ PanOptix Presbyopia Correcting IOL</intervention_name>
    <description>UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.</description>
    <arm_group_label>PanOptix IOL</arm_group_label>
    <other_name>Model TFNT00</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL</description>
    <arm_group_label>PanOptix IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Able to comprehend and sign an informed consent form;&#xD;
&#xD;
          -  Able to complete all study visits required in the protocol;&#xD;
&#xD;
          -  Chinese; diagnosed with cataracts in both eyes;&#xD;
&#xD;
          -  Planned bilateral cataract removal by routine phacoemulsification;&#xD;
&#xD;
          -  Pre-operative regular corneal astigmatism of less than 1.0 diopter (D);&#xD;
&#xD;
          -  Pre-operative best corrected distance visual acuity (BCDVA) worse than or equal to 0.3&#xD;
             LogMAR in each eye;&#xD;
&#xD;
          -  Potential postoperative best corrected distance visual acuity (BCDVA) of 0.3 logMAR or&#xD;
             better in both eyes based on the investigator expert medical opinion.&#xD;
&#xD;
          -  Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Glaucoma, diabetic retinopathy, retinitis pigmentosa and any pathologic changes&#xD;
             associated with the optic nerve;&#xD;
&#xD;
          -  Clinically significant corneal diseases;&#xD;
&#xD;
          -  Clinically significant/severe dry eye that would affect study measurements based on&#xD;
             the investigator's expert medical opinion;&#xD;
&#xD;
          -  Previous intraocular or corneal surgery;&#xD;
&#xD;
          -  Pregnancy or lactation during study or planning to be pregnant/lactating;&#xD;
&#xD;
          -  Systemic medications that, in the opinion of the Investigator, may confound the&#xD;
             outcome or increase the risk to the subject;&#xD;
&#xD;
          -  Other planned ocular surgical procedures;&#xD;
&#xD;
          -  Patients who desire monovision.&#xD;
&#xD;
          -  Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Project Manager, Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon (China) Ophthalmic Product Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alcon Investigator 6610</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8156</name>
      <address>
        <city>Peking</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8157</name>
      <address>
        <city>Shandong</city>
        <zip>250002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8159</name>
      <address>
        <city>Sichuan</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 7749</name>
      <address>
        <city>Tianjin</city>
        <zip>300384</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Intraocular Lens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

